At LUMICKS, our goal is to improve human health by unlocking the power of dynamic single-molecule and cell avidity analysis. We empower researchers with tools that provide unparalleled insight into the fundamental cause of disease and the potential for drug optimization. With the rate of progress in biological research accelerating exponentially, the need to understand how biological processes occur at a molecular level is becoming increasingly important.
LUMICKS is the world-leader in dynamic single-molecule (DSM) and cell avidity analysis and is focused on establishing these breakthrough approaches as a standard analytical method in molecular biology and immunotherapy. We achieve this through the increasingly rapid adoption by scientific KOLs and publications by early adopters, as well as through our growing biotech customer base.
With a complementary and growing product line, LUMICKS is well positioned to capitalize on the market opportunity for this technology across the academic and pharma segments.
LUMICKS is focused on
driving the adoption of DSM
in molecular research
The dynamic process of DNA replication at the single-molecule scale. Credits: Originally created by DNA Learning Center for www.dnai.org
Capture molecular interactions
Dynamic single-molecule analysis explained
All biological processes ultimately take place at the molecular level, all diseases arise at this level, and practically all drugs act at this level. Thus, there is an immense need to understand how these molecular interactions take place.
The challenge is that current life science tools working at the molecular level either measure static structure or average binding kinetics. The crucial and often very complex mechanistic details of the underlying dynamic process of protein interactions are not revealed. Dynamic single-molecule analysis reveals these details.
The unique ability to combine live imaging, manipulation and force-displacement measurement with Angstrom precision, provides single-protein imaging resolution and base pair resolution of molecular conformational changes. Taken together, this gives the crucial dynamic and functional mechanistic information that is complementary to protein structure (crystallography) and ensemble average kinetics (SPR).Explore our product range
Diving into immuno-oncology
Cell avidity analysis explained
In the last few years, the onset of immunotherapy has begun to change the landscape of medicine. The key parameter in determining the effectiveness of immunotherapies is the overall strength of interaction, the Avidity, between an immune cell and its target. This is also key for the development and application of effective immuno-oncology therapies.
However, cell-cell avidity is a complex combination of many interactions between receptors, antigens, co-factors etc. And the combined interaction forces could not be directly measured to date. Gold-standard technologies, like SPR, only measure the affinity of a molecular interaction, while Tetramer-stained Flow Cytometry can measure the abundance of, say, a certain receptor.
Now with LUMICKS’ z-Movi®, the avidity between immune cells and cancer cells can for the first time be measured directly, in a label-free and high-throughput way.Explore the technology
The LUMICKS Team
We are a company of visionaries
LUMICKS is managed by an experienced team with diverse backgrounds. They combine business experience with technical expertise and a strong drive for growth and impact through customer success.Meet the Team
Preserving the environment
Environmental, Social, Governance
LUMICKS is committed to preserving the environment for future generations through minimizing our environmental footprint. We design our products for low energy consumption and our employees fly CO2 neutral.Press release: LUMICKS continues efforts to offset CO2 emissions generated by global travel